Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy(Université Toulouse III - Paul Sabatier), Bruno Guerci(Inserm), Jean‐Michel Halimi(Centre Hospitalier Universitaire de Tours), François Diévart, Patrice Darmon(Assistance Publique Hôpitaux de Marseille)
Cited by 123
Related Papers
Sex differences in metabolic regulation and diabetes susceptibility
|Diabetologia|2019|876
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
|Diabetes Care|2019|282
Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*
|Nephrology Dialysis Transplantation|2017|228
Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population
|Kidney International|2000|191